On the mechanism of inhibition of p27 degradation by 15-deoxy- Δ12,14-prostaglandin J 2 in lymphoblasts of Alzheimer's disease patients

Cellular and Molecular Life Sciences

Volumn 65, Issue 21, 2008, Pages 3507-3519

  Munoz U ^a   Bartolome F ^a   Esteras, N ^a   Bermejo Pareja, F ^b,c   Martin Requero A ^a,d  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Alzheimer's disease; Ca 2+ calmodulin; Cell proliferation; Cyclopentenone prostaglandins; Lymphocytes; p27; PI3K Akt; Proteasome activity

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 9,10 DIHYDRO 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE B; PROTEIN P27; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LYMPHOBLAST; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CALMODULIN; CELL CYCLE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HALF-LIFE; HUMANS; LYMPHOCYTES; NERVE TISSUE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROSTAGLANDIN D2; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 55549110369     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8411-9     Document Type: Article

References (58)

1. McGeer, P. L. and McGeer, E. G. (2007) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol. Aging 28, 639-647.
2. McGeer, P. L., Rogers, J. and McGeer, E. G. (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J. Alzheimers Dis. 9, 271-276.
3. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. and Kliewer, S. A. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
4. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J. and Willoughby, D. A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5, 698-701.
5. 2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J. Immunol. 171, 6827-6837.
6. 2 and 2-cyclopenten-1-one: Role of the heat shock response. Mol. Pharmacol. 64, 85-93.
7. Blanco, M., Moro, M. A., Davalos, A., Leira, R., Castellanos, M., Serena, J, Vivancos, J., Rodriguez-Yanez, M., Lizasoain, I. and Castillo, J. (2005) Increased plasma levels of 15-deoxydelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 36, 1189-1194.
8. Han, S. W., Greene, M. E., Pitts, J., Wada, R. K. and Sidell, N. (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin. Cancer Res. 7, 98-104.
9. Chaffer, C. L., Thomas, D. M., Thompson, E. W. and Williams, E. D. (2006) PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6, 53.
10. Arendt, T, (2003) Synaptic plasticity and cell cycle activation in neurons are alternative effectors pathways: The 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 71, 83-248.
11. Herrup, K., Neve, R., Ackerman, S. L. and Copani, A. (2004) Divide and die: Cell cycle events as triggers of nerve cell death. J. Neurosci. 24, 9232-9239.
12. Nagy, Z. (2005) The last neuronal division: A unifying hypothesis for the pathogenesis of Alzheimer's disease. J. Cell. Mol. Med. 9, 531-541.
13. Neve, R. L. and Mcphie, D. L. (2006) The cell cycle as therapeutic target for Alzheimer's disease. Pharmacol. Ther. 111, 99-113.
14. Nagy, Z. (2000) Cell cycle regulatory failure in neurones: Causes and consequences. Neurobiol. Aging 21, 761-769.
15. Casadesus, G., Zhu, X., Atwood, C. S., Webber, K. M., Perry, G., Bowen, R. L. and Smith, M. A. (2004) Beyond estrogen: Targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 3, 281-285.
16. Webber, K. M., Raina, A. K., Marlatt, M. W., Zhu, X., Prat, M. I., Morelli, L., Casadesus, G., Perry, G. and Smith, M. A. (2005) The cell cycle in Alzheimer disease: A unique target for neuropharmacology. Mech. Ageing Dev. 126, 1019-1025.
17. Huang, H. M., Martins, R., Gandy, S., Etcheberrigaray, R., Ito, E., Alkon, D. L., Blass, J. and Gibson, G. (1994) Use of cultured fibroblasts in elucidating the pathophysiology and diagnosis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 747, 225-244.
18. Mecocci, P., Polidori, M. C., Ingegni, T., Cherubini, A., Chionne, F., Cecchetti, R. and Senin, U. (1998) Oxidative damage to DNA in lymphocytes from AD patients. Neurology 51, 1014-1017.
19. Tatebayashi, Y., Takeda, M., Kashiwagi, Y., Okochi, M., Kurumadani, T., Sekiyama, A., Kanayama, G., Hariguchi, S. and Nishimura, T. (1995) Cell-cycle-dependent abnormal calcium response in fibroblasts from patients with familial Alzheimer's disease. Dementia 6, 9-16.
20. Nagy, Z. S., Combrinck, M., Budge, M. and McShane,R. (2002) Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci. Lett. 317, 81 -84.
21. Neitzel, H. (1986) A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum. Genet. 73, 320-326.
22. Beatty, P. R., Krams, S. M. and Martinez, O. M. (1997) Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J. Immunol. 158, 4045-4051.
23. Minami, R., Watanabe, Y., Kudoh, T., Suzuki, M., Oynagi, K., Orii, T. and Nakao, T. (1978) Lysosomal acid hydrolases in established lymphoblastoid cell lines transformed by Epstein-Barr virus, from patients with genetic lysosomal storage diseases. Hum. Genet. 44. 79-87.
24. 2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol. Dis. 13, 254-263.
25. de las Cuevas, N., Muñoz, U., Hermida, O. G. and Martín-Requero, A. (2005) Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiol. Aging 26, 615-624.
26. Muñoz, U., Bartolomé, F., Bermejo, F. and Martín-Requero, A. (2008) Enhanced proteasome-dependent degradation of the CDK inhibitor p27 (kip1) in immortalized lymphocytes from Alzheimer's dementia patients. Neurobiol. Aging 29, 1474-1484.
27. 2+/calmodulin and ERK1/2 signaling pathways. Cell. Mol. Life Sci. 64, 1437-1448.
28. 12,14-prostaglandin J2 inhibits G1/S transition and retinoblastoma protein phosphorylation in immortalized lymphocytes from Alzheimer's disease patients. Exp. Neurol. 195, 508-517.
29. Ibarreta, D., Urcelay, E., Parrilla, R. and Ayuso, M. S. (1998) Distinct pH homeostatic features in lymphoblasts from Alzheimer's disease patients. Ann. Neurol. 44, 216-222.
30. Koistinen, P. (1987) Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological diseases. Scan. J. Clin. Lab. Invest. 47, 709-714.
31. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P. and Anderson, K. C. (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 99, 4079-4086.
32. Krishan, A. (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66, 188-193.
33. Dick, L. R., Cruikshank, A. A., Destree, A. T., Grenier, L., McCormack, T. A., Melandri, F. D., Nunes, S. L., Palombella, V. J., Parent, L. A., Plamondon, L. and Stein, R. L. (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272, 182-188.
34. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., DelSal, G., Chau, V., Yew, P. R., Draetta, G. F. and Rolfe, M. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685.
35. Kip1 at threonine 157 and modulation of its cellular localization. Nat. Med. 8, 1145-1152.
36. Kip1 and control of cyclin D1 expression. Leukemia 17, 2157-2167.
37. Joyal, J. L., Burks, D. J., Pons, S., Matter, W. F., Vlahos, C. J., White, M. F. and Sacks, D. B, (1997) Calmodulin activates phosphatidylinositol 3-kinase. J. Biol. Chem. 272, 28183-28186.
38. Perez-Garcia, M. J., Cena, V., de Pablo, Y., Llovera, M., Comella, J. X. and Soler, R. M. (2004) Glial cell line-derived neurotrophic factor increases intracellular calcium concentration. Role of calcium/calmodulin in the activation of the phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 279, 6132-6142.
39. 2 in MCF7 breast cancer cells. Biochemistry 42, 5429-5437.
40. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
41. Marx, N., Schönbeck, U., Lazar, M. A., Libby, P. and Plutzky, J. (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83, 1097-1103.
42. 2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int. 61, 1957-1967.
43. 2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett. 501, 24-30.
44. Janabi, N. (2002) Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-delta (12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. J. Immunol. 168, 4747-4755.
45. 2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276, 35530-35536.
46. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor-independent mechanisms involving reactive oxygenated species. J. Biol. Chem. 277, 29681-29685.
47. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J. Immunol. 168, 1372-1379.
48. Giri, S., Rattan, R., Singh, A. K. and Singh, I. (2004) The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaBp300 pathway independent of peroxisome proliferator-activated receptor gamma. J. Immunol. 173, 5196-5208.
49. 1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 95, 15406-15411.
50. Radu, A., Neubauer, V., Akagi, T., Hanafusa, H. and Georgescu, M. M. (2003) PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell. Biol. 23, 6139-6349.
51. Liang, J. and Slingerland, J. M, (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 339-345.
52. Carrano, A,C,, Eytan, E., Hershko, A. and Pagano, M. (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193-199.
53. Nakayama, K., Nagahama, H., Minamishima, Y. A., Matsumoto, M., Nakamichi, I., Kitagawa, K, Shirane, M., Tsunematsu, R., Tsukiyama,T., Ishida,N.,Kitagawa, M.,Nakayama, K. and Hatakeyama, S. (2000) Targeted disruption of Skp2 results in accumulation of cyclin E and p27 (Kip1), polyploidy and centrosome overduplication. EMBO J. 19, 2069-2081.
54. Blandini, F., Sinforiani, E., Pacchetti,C., Samuele, A., Bazzini, E., Zangaglia, R., Nappi, G. and Martignoni, E. (2006) Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66, 529-534.
55. Rickle, A., Bogdanovic, N., Volkman, I., Winblad, B., Ravid, R. and Cowburn, R. F. (2004) Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15, 955-959.
56. Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R. and O'Neill, C. (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution ofAkt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93, 105-117.
57. McShea, A., Harris, P. L. R., Webster, K. R., Wahl, A. P. and Smith, M. A. (1997) Abnormal expression of cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am. J. Pathol. 150, 1933-1939.
58. Ogawa, O., Lee, H. G., Zhu, X., Raina, A., Harris, P. L., Castellani, R. J., Perry, G. and Smith, M. A. (2003) Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell 2, 105-110.